
Professional Certificate in Diabetes Health Coaching Services

Pharmacology of Diabetes Medications

Acarbose

Related terms: alpha-glucosidase inhibitor, postprandial glucose. Acarbose slows carbohydrate digestion by inhibiting intestinal enzymes that break down complex sugars. It is taken with the first bite of a meal and reduces the rise in blood glucose after eating. Practical application: Useful for patients who have pronounced post-meal spikes and who prefer oral therapy over insulin. Challenges include gastrointestinal side effects such as flatulence and diarrhea, which may limit adherence.

Albiglutide

Related terms: GLP-1 receptor agonist, weekly dosing. Albiglutide is a long-acting glucagon-like peptide-1 analog that enhances glucose-dependent insulin secretion and suppresses glucagon. It is administered once weekly by subcutaneous injection. Example: A patient with established cardiovascular disease may benefit from the weekly schedule, improving convenience. Challenges: Injection site reactions and a relatively modest weight-loss effect compared with other GLP-1 agents.

Alpha-glucosidase inhibitors

Related terms: acarbose, miglitol, voglibose. This drug class delays carbohydrate absorption by inhibiting brush-border enzymes. They are most effective at lowering postprandial glucose excursions. Practical use: Can be combined with metformin for additive effect. Limitations include poor tolerability due to bloating and the need to dose with each meal, which can affect compliance.

Amylin analogues

Related terms: pramlintide, postprandial control. Amylin is a hormone co-secreted with insulin; its analogues slow gastric emptying, suppress glucagon, and promote satiety. Pramlintide is administered before meals and is indicated for type 1 and insulin-treated type 2 diabetes. Example: A patient experiencing nocturnal hypoglycemia may benefit from the glucagon-suppressing effect. Challenges: Injection requirement, risk of nausea, and the need for careful carbohydrate counting.

Basal insulin

Related terms: glargine, detemir, degludec. Basal insulin provides a steady low-level insulin supply to control fasting glucose. Long-acting analogues such as glargine and degludec have flat pharmacodynamic profiles, reducing nocturnal hypoglycemia risk. Practical application: Often initiated when oral agents fail to achieve target HbA1c. Challenges include dose titration, monitoring for hypoglycemia, and patient reluctance to start injections.

Beta-cell function

Related terms: insulin secretion, HOMA- β . Beta-cell function reflects the pancreas's ability to produce insulin

in response to glucose. It declines progressively in type 2 diabetes. Assessment tools such as the Homeostatic Model Assessment (HOMA- β) help clinicians gauge residual capacity. Practical relevance: Therapies that preserve beta-cell health (e.g., GLP-1 agonists, DPP-4 inhibitors) may be prioritized early. Challenges: Measuring function in routine practice is limited by assay availability.

Biguanides

Related terms: metformin, lactic acidosis. Biguanides decrease hepatic glucose production and improve peripheral insulin sensitivity. Metformin is the prototype and first-line agent for type 2 diabetes. Example: A newly diagnosed overweight patient typically starts metformin at low dose to minimize gastrointestinal upset. Challenges: Contraindications in renal impairment, risk of lactic acidosis (rare), and the need for dose titration.

Canagliflozin

Related terms: SGLT2 inhibitor, renal glucose excretion. Canagliflozin blocks the sodium-glucose cotransporter-2 in the proximal tubule, promoting urinary glucose loss. It lowers HbA1c, reduces body weight, and modestly lowers blood pressure. Practical use: May be added to metformin for synergistic effect. Challenges: Increased risk of genital mycotic infections, volume depletion, and rare cases of ketoacidosis, especially in low-carbohydrate diets.

Cardiovascular outcome trials (CVOTs)

Related terms: EMPA-REG, LEADER, DECLARE-TIMI. CVOTs evaluate the impact of diabetes medications on major adverse cardiovascular events. Positive outcomes have reshaped prescribing guidelines, favoring agents with proven cardiovascular benefit. Practical application: A patient with established atherosclerotic disease may be steered toward an SGLT2 inhibitor or GLP-1 agonist with CVOT-positive data. Challenges: Interpreting trial results, cost considerations, and insurance coverage.

Combination therapy

Related terms: fixed-dose combination, metformin-sitagliptin. Combining agents with complementary mechanisms can improve glycemic control while minimizing dose-related side effects. Fixed-dose combinations simplify regimens, enhancing adherence. Example: Metformin plus a DPP-4 inhibitor is a common first-line step-up. Challenges include limited flexibility in dose adjustment and potential for additive adverse effects.

Dapagliflozin

Related terms: SGLT2 inhibitor, heart failure. Dapagliflozin lowers glucose by inhibiting renal glucose reabsorption and has been shown to reduce hospitalization for heart failure. Practical use: Recommended for patients with type 2 diabetes and reduced ejection fraction, regardless of glycemic control. Challenges: Similar to other SGLT2 inhibitors—genital infections, volume depletion, and rare euglycemic ketoacidosis.

DPP-4 inhibitors

Related terms: sitagliptin, saxagliptin, linagliptin. Dipeptidyl peptidase-4 inhibitors prevent the breakdown

of incretin hormones, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon. They are weight-neutral and have low hypoglycemia risk when used alone. Practical application: Useful for patients who cannot tolerate metformin or who need modest HbA1c reduction. Challenges: Some agents have been linked to increased risk of heart failure (e.G., Saxagliptin) and pancreatitis, though data are not definitive.

Durability of glycemic control

Related terms: beta-cell preservation, progressive loss. Durability refers to how long a therapy maintains target glucose levels before additional treatment is required. Agents that improve insulin sensitivity (e.G., Metformin, thiazolidinediones) or augment incretin pathways tend to have greater durability. Practical relevance: Selecting a regimen with proven long-term efficacy can delay treatment intensification. Challenges: Real-world data are limited, and patient adherence heavily influences durability.

Emtricitabine/tenofovir

Related terms: HIV-diabetes drug interaction. While not a diabetes medication, these antiretrovirals can affect glucose metabolism and interact with certain diabetes agents, especially those cleared renally. Practical note: Clinicians should monitor renal function and adjust doses of metformin or SGLT2 inhibitors accordingly. Challenges: Overlapping toxicities and the need for coordinated care between HIV and diabetes providers.

Empagliflozin

Related terms: SGLT2 inhibitor, EMPA-REG OUTCOME. Empagliflozin reduces glucose via urinary excretion and has demonstrated cardiovascular mortality reduction in the EMPA-REG trial. It also slows progression of diabetic kidney disease. Practical use: First choice for patients with high cardiovascular risk. Challenges: Similar safety profile to other SGLT2 inhibitors, with added caution in patients on diuretics.

Glucagon-like peptide-1 (GLP-1) receptor agonists

Related terms: exenatide, liraglutide, semaglutide. GLP-1 agonists mimic the incretin hormone, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. They produce notable weight loss and have cardiovascular benefit in several agents. Practical application: Ideal for overweight patients needing strong HbA1c reduction. Challenges: Injectable route (though oral semaglutide exists), nausea, and cost.

Glucotoxicity

Related terms: chronic hyperglycemia, beta-cell dysfunction. Persistent high glucose levels impair insulin secretion and promote oxidative stress, leading to progressive beta-cell failure. Understanding glucotoxicity underscores the importance of early, effective glycemic control. Practical relevance: Clinicians may use agents with rapid onset (e.G., Insulin, GLP-1 agonists) to break the cycle. Challenges: Patient adherence and fear of hypoglycemia can impede aggressive treatment.

Glucose-dependent insulintropic polypeptide (GIP)

Related terms: DPP-4 inhibitor, incretin effect. GIP is another incretin hormone that stimulates insulin release. While DPP-4 inhibitors increase GIP levels, the therapeutic impact of GIP alone is modest compared with GLP-1. Emerging dual-agonists target both receptors for synergistic effect. Practical note: Future agents may combine GIP and GLP-1 activity to enhance efficacy. Challenges: Limited clinical data and potential for adverse gastrointestinal effects.

Glucose monitoring technologies

Related terms: CGM, SMBG, A1C. Continuous glucose monitoring (CGM) provides real-time glucose trends, while self-monitoring of blood glucose (SMBG) offers snapshot values. These tools guide medication titration, especially for insulin and sulfonylureas. Practical example: A patient on basal-bolus insulin uses CGM data to adjust bolus doses. Challenges: Sensor cost, data overload, and need for patient education.

Guideline-driven therapy

Related terms: ADA, EASD, stepwise approach. Clinical practice guidelines recommend a patient-centered, stepwise algorithm: Lifestyle → metformin → add-on agents based on comorbidities (e.g., SGLT2 inhibitor for heart failure). Practical application: Health coaches use these pathways to personalize plans. Challenges: Keeping up with evolving recommendations and integrating them into individualized coaching.

Hemoglobin A1c (HbA1c)

Related terms: glycated hemoglobin, target 7%. HbA1c reflects average glucose over 2-3 months and is the primary metric for long-term control. Targets may be individualized based on age, comorbidities, and hypoglycemia risk. Practical use: Medication efficacy is often judged by HbA1c reduction. Challenges: Variability due to hemoglobinopathies, anemia, and patient factors that may mask true glucose levels.

Insulin analogues

Related terms: lispro, aspart, glulisine, rapid-acting. Rapid-acting analogues mimic physiological insulin peaks after meals, improving postprandial control. They are often combined with basal insulin in a basal-bolus regimen. Practical example: A patient using carbohydrate counting can match rapid-acting doses to meal size. Challenges: Timing errors, risk of hypoglycemia, and injection burden.

Insulin degludec

Related terms: ultra-long-acting, flexible dosing. Degludec forms multi-hexamer chains, providing a flat, 42-hour duration, allowing dosing at varying times of day. Practical benefit: Reduces nocturnal hypoglycemia and offers flexibility for shift workers. Challenges: Higher cost and need for patient education on the unique pharmacokinetic profile.

Insulin pump therapy

Related terms: continuous subcutaneous insulin infusion, CSII. Pumps deliver rapid-acting insulin continuously, allowing precise basal rate adjustments and bolus dosing for meals. They improve glycemic variability and reduce hypoglycemia in many type 1 patients. Practical use: Health coaches can support patients in pump programming and troubleshooting. Challenges: Device cost, skin infections, and the

learning curve for pump management.

Insulin resistance

Related terms: metabolic syndrome, hyperinsulinemia. Insulin resistance describes diminished cellular response to insulin, leading to compensatory hyperinsulinemia and eventual glucose intolerance. It is central to type 2 diabetes pathogenesis. Practical implication: Agents that improve sensitivity (e.g., Metformin, thiazolidinediones) target this defect. Challenges: Lifestyle changes are essential but often difficult to sustain.

Liraglutide

Related terms: GLP-1 receptor agonist, LEADER trial. Liraglutide is a once-daily GLP-1 analog with proven cardiovascular benefit in the LEADER trial. It produces significant weight loss and reduces major adverse cardiac events. Practical use: Ideal for overweight patients with high CV risk. Challenges: Injection requirement, nausea, and higher price point.

Meglitinides

Related terms: repaglinide, nateglinide, short-acting sulfonylurea. Meglitinides stimulate insulin release with a rapid onset and short duration, matching mealtime glucose spikes. They are taken before each meal, offering flexibility for irregular eating patterns. Practical example: A patient with unpredictable meal times may prefer meglitinides over sulfonylureas. Challenges: Need for multiple daily dosing and risk of hypoglycemia if meals are skipped.

Metformin

Related terms: biguanide, hepatic gluconeogenesis. Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity, making it the cornerstone of type 2 diabetes management. It is weight-neutral and has a low hypoglycemia risk. Practical application: Initiated at 500 mg once daily and titrated to 2000 mg as tolerated. Challenges: Gastrointestinal upset, contraindication in severe renal impairment, and rare risk of lactic acidosis.

Miglitol

Related terms: alpha-glucosidase inhibitor, postprandial control. Miglitol competitively inhibits intestinal enzymes, slowing carbohydrate absorption. It is taken with each meal and can lower postprandial glucose without causing significant weight loss. Practical use: May be combined with metformin for additive effect. Challenges: Similar gastrointestinal adverse events to acarbose, leading to poor long-term adherence.

Na⁺/glucose cotransporter-2 (SGLT2) inhibitors

Related terms: canagliflozin, dapagliflozin, empagliflozin. This class reduces renal glucose reabsorption, increasing urinary glucose excretion. Benefits include HbA1c reduction, weight loss, blood pressure lowering, and cardiovascular/kidney protection. Practical application: Often added after metformin failure. Challenges: Genital infections, volume depletion, and rare euglycemic ketoacidosis, especially in low-carbohydrate diets.

Nephroprotective effects

Related terms: albuminuria reduction, SGLT2 inhibitors. Certain diabetes medications, notably SGLT2 inhibitors and GLP-1 agonists, slow progression of diabetic kidney disease by reducing intraglomerular pressure and albuminuria. Practical relevance: Clinicians may prioritize these agents in patients with early CKD. Challenges: Monitoring renal function, dose adjustment in advanced CKD, and insurance coverage.

Non-insulin injectable therapies

Related terms: GLP-1 agonists, amylin analogues. These agents are administered subcutaneously but do not replace insulin. They act via incretin pathways or satiety mechanisms, providing glucose lowering with weight benefits. Practical example: A patient reluctant to start insulin may begin with a GLP-1 agonist. Challenges: Injection aversion, gastrointestinal side effects, and higher cost.

Obesity and diabetes pharmacotherapy

Related terms: weight-loss, bariatric effects. Many diabetes agents influence body weight: Metformin and GLP-1 agonists promote loss, while sulfonylureas and insulin may cause gain. Understanding these effects helps tailor therapy to individual goals. Practical use: A health coach may align medication choice with weight-management counseling. Challenges: Balancing glycemic efficacy with weight considerations, especially in patients with limited insurance coverage.

Oral semaglutide

Related terms: GLP-1 receptor agonist, tablet formulation. The first oral GLP-1 agonist combines semaglutide with an absorption enhancer to permit gastrointestinal uptake. It offers the benefits of GLP-1 therapy without injections. Practical use: Patients averse to needles may achieve comparable HbA1c reduction. Challenges: Strict dosing schedule (fasting state), gastrointestinal tolerability, and cost.

Pioglitazone

Related terms: thiazolidinedione, PPAR- γ agonist. Pioglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor- γ , leading to decreased hepatic glucose output and increased peripheral uptake. It also reduces triglycerides and may have cardiovascular benefit. Practical application: Useful for patients with significant insulin resistance. Challenges: Weight gain, fluid retention, risk of heart failure exacerbation, and rare hepatic toxicity.

Postprandial glucose

Related terms: PPG, meal-time control. Postprandial glucose reflects blood sugar levels 1-2 hours after a meal and is a major determinant of overall HbA1c. Targeting PPG can be achieved with rapid-acting insulin, meglitinides, alpha-glucosidase inhibitors, or GLP-1 agonists. Practical example: A patient with high PPG spikes despite fasting control may add a GLP-1 agent. Challenges: Timing of medication relative to meals and patient adherence to dietary recommendations.

Pramlintide

Related terms: amylin analogue, postprandial control. Pramlintide is a synthetic amylin analogue

administered before meals to slow gastric emptying, suppress glucagon, and promote satiety. It is adjunctive to insulin therapy in both type 1 and type 2 diabetes. Practical use: Can reduce insulin dose requirements and mitigate nocturnal hypoglycemia. Challenges: Requires multiple daily injections, nausea, and meticulous carbohydrate counting.

Renal dosing adjustments

Related terms: eGFR, drug clearance. Many diabetes medications are cleared renally; dose reductions or avoidance are necessary in chronic kidney disease (CKD). For example, metformin is contraindicated below eGFR 30 mL/min/1.73 M², while SGLT2 inhibitors are limited below eGFR 45 mL/min/1.73 M² (varies by agent). Practical relevance: Health coaches must be aware of renal thresholds to avoid adverse events. Challenges: Frequent monitoring of renal function and patient education on dose changes.

Risk of hypoglycemia

Related terms: insulin, sulfonylureas, patient safety. Hypoglycemia is a major barrier to optimal diabetes management, especially with insulin and insulin secretagogues. Symptoms range from mild shakiness to severe neuroglycopenia. Practical strategies: Educate patients on recognizing signs, using carbohydrate rescue, and adjusting doses based on glucose trends. Challenges: Balancing tight glycemic targets with safety, especially in elderly or comorbid populations.

Sitagliptin

Related terms: DPP-4 inhibitor, renal dosing. Sitagliptin inhibits DPP-4, extending the activity of endogenous GLP-1 and GIP. It is weight-neutral and has a low hypoglycemia risk when used alone. Practical use: Often combined with metformin for additive HbA1c reduction. Challenges: Dose adjustment required in renal impairment and rare reports of pancreatitis.

Thiazolidinediones (TZDs)

Related terms: pioglitazone, rosiglitazone, PPAR-γ. TZDs enhance insulin sensitivity by activating PPAR-γ, improving glucose uptake in adipose and muscle tissue. They lower HbA1c and have favorable effects on lipid profiles. Practical application: Beneficial in patients with marked insulin resistance. Challenges: Weight gain, fluid retention, increased risk of heart failure, and potential bone fracture risk.

Therapeutic inertia

Related terms: clinical inertia, delayed intensification. Therapeutic inertia describes the failure to advance therapy despite suboptimal glycemic control. It contributes to prolonged hyperglycemia and complications. Practical approach: Set clear HbA1c targets, schedule regular medication reviews, and empower patients through education. Challenges: Provider hesitation, patient fear of side effects, and insurance barriers.

Uric acid elevation

Related terms: canagliflozin, gout risk. Some SGLT2 inhibitors, notably canagliflozin, may modestly increase serum uric acid, potentially precipitating gout attacks. Practical note: Monitor uric acid in patients with prior gout and counsel on hydration. Challenges: Balancing cardiovascular benefits against gout risk, especially in

patients with a history of hyperuricemia.

Voglibose

Related terms: alpha-glucosidase inhibitor, postprandial glucose. Voglibose slows carbohydrate digestion similarly to acarbose, reducing postprandial glucose excursions. It is taken with each meal and is available in several Asian markets. Practical use: May be combined with metformin for enhanced postprandial control. Challenges: Gastrointestinal side effects and limited availability in some regions.

Weight management considerations

Related terms: obesity, GLP-1 agonists, SGLT2 inhibitors. Medication choice can influence body weight; agents like GLP-1 agonists and SGLT2 inhibitors promote loss, while insulin and sulfonylureas may cause gain. Health coaches should integrate weight goals into medication discussions. Practical example: A patient seeking weight reduction may be steered toward liraglutide. Challenges: Patient expectations, insurance coverage, and side-effect profiles.

Zinc-insulin analogues

Related terms: insulin glulisine, rapid-acting. Zinc-insulin formulations contain zinc to stabilize the insulin molecule, allowing rapid absorption after subcutaneous injection. Glulisine is a zinc-insulin analogue with a quick onset, useful for post-meal dosing. Practical application: Patients performing carbohydrate counting can match glulisine dose to meal carbohydrate content. Challenges: Timing accuracy, risk of hypoglycemia if meals are delayed.